Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has initiated a Phase I/III clinical trial for HLX13, a biosimilar of ipilimumab, targeting unresectable advanced hepatocellular carcinoma (HCC) patients in China [2]. HLX13 Information and Research Status - HLX13 is a biosimilar of ipilimumab developed by the group, intended for treating multiple cancers including melanoma, renal cell carcinoma, colorectal cancer, HCC, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell carcinoma [3]. - As of April 2025, the group has invested approximately RMB 104 million (about $15 million) in the development of HLX13 [3]. - According to IQVIA MIDASTM data, global sales of ipilimumab formulations are projected to reach approximately $2.873 billion in 2024 [3].

随后，专家团队现场考察了已建成的应用示范线，肯定了该项目在"产学研用"协同创新中的示范效应， 同时降低了对石油基资源的依赖，符合绿色制造与可持续发展的未来趋势，一致同意通过应用示范现场 鉴定。 鉴定会的顺利举行，标志着长阳科技该项目已从技术研发向商业化应用迈出了关键一步。长阳科技相关 人士称，作为项目的参与方之一，公司将继续发挥多年来在光学膜材料领域深厚的技术积淀，加速生物 基材料在功能膜领域的研发与应用，助力我国从"材料大国"向"材料强国"迈进。 本报讯(记者吴奕萱)5月12日，由中国科学院宁波材料所牵头、宁波长阳科技股份有限公司(以下简称"长 阳科技")参与的2021年度国家重点研发计划"低成本高性能生物基聚酯和聚碳酸酯的制备与产业化"项目 课题五"低成本CBDO(一种有机聚合物单体)及高Tg(共聚酯薄膜玻璃化转变温度)、高抗冲击透明聚酯产 业化示范与应用"任务——高Tg、抗冲击透明共聚酯功能膜和容器应用示范的现场鉴定会在长阳尖端材 料研究院举行。来自宁波大学、浙大宁波理工学院、激智科技（300566）等科研单位的专家评审团，对 项目成果进行了专业评审。 鉴定会上，长阳科技副总经理、研究院院长周玉波博士作 ...

证券代码：688299 证券简称：长阳科技 公告编号：2025-033 宁波长阳科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 13 日 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事7人，以现场结合通讯方式出席7人； 2、 公司在任监事3人，以现场方式出席3人； 3、 董事会秘书章殷洪先生出席了本次会议；高级管理人员列席了本次会议。 二、 议案审议情况 （一） 非累积投票议案 （二） 股东大会召开的地点：宁波市江北区庆丰路 999 号公司一楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 58 | | --- | --- | | 普通股股东人数 | 58 | | 2、出席会议的股东所持有的表决权数量 | 57,820,293 | | 普通股 ...

国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 Grandall Law Firm (Shanghai) 中国 上海 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼，200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China, 200085 电话/TEL: (8621) 5234-1668 传真/FAX: (8621) 5234-1670 关于宁波长阳科技股份有限公司 2024年年度股东大会的法律意见书 致：宁波长阳科技股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受宁波长阳科技股份有限公 司（以下简称"公司"）委托，指派本所律师出席公司 2024 年年度股东大会（以 下简称"本次股东大会"）。本所律师根据《中华人民共和国证券法》（以下简称 "《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、《上 市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规、部门规章和 规范性文件以及《宁波长阳科技股份有限公司章程》（以下简称"《公司章程》"） ...

宁波长阳科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688299 证券简称：长阳科技 宁波长阳科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 宁波长阳科技股份有限公司 2024 年年度股东大会会议资料 宁波长阳科技股份有限公司 2024 年年度股东大会会议资料目录 | 宁波长阳科技股份有限公司 | 2024 年年度股东大会会议须知 3 | | --- | --- | | 宁波长阳科技股份有限公司 | 年年度股东大会会议议程 5 2024 | | 议案一：关于公司 2024 | 年年度报告及摘要的议案 7 | | 议案二：关于公司独立董事 | 2024 年度述职报告的议案 8 | | 议案三：关于公司 2024 | 年度董事会工作报告的议案 9 | | 议案四：关于公司 2024 | 年度监事会工作报告的议案 10 | | 议案五：关于公司 2024 | 年度财务决算报告的议案 11 | | 议案六：关于公司 2024 | 年度利润分配预案的议案 12 | | 议案七：关于公司 2025 | 年度财务预算报告的议案 13 | | 议案八：关于公司 2024 | 年度募 ...

长阳科技 20250429 摘要 • 长阳科技一季度利润同比增长 72%，主要得益于反射膜业务毛利率提升、 胶膜业务亏损大幅减少以及合肥、宁波两地隔膜和胶膜业务亏损收窄。反 射膜业务收入虽略有下降，但毛利率从 36.8%升至 37.34%，盈利能力相 对稳定。 • 预计全年反射膜业务将保持个位数增长，受益于大尺寸电视需求增加和 BEMAP 客户小尺寸增量导入。原油价格下滑及中小尺寸占比增加也有助 于提升毛利率，一季度已提升 0.5 个百分点至 37.34%。 • 光学基膜一季度表现不佳，收入同比减少 400 万元，毛利率为负 11%， 主要因停工导致产能未充分发挥。目前月产能 1,500 吨，满产情况下月营 收可达 4,500 万元，未来有望通过生产恢复和优化管理提升业绩。 • 公司正在积极推进半固态隔膜和 CPI 膜的研发和生产，固态电子复合膜基 材已进入客户验证阶段，主要客户包括松下、三星 SDI、宁德时代等，预 计 2027 年小规模装车交付。 • 固态电池复合膜基膜设备造价低廉，成本相对较低，一条设备投资约五六 千万元，产能 5,000 万平方米，交付周期短，约 8-12 个月，设备相对自 主可控，这 ...

Policy Developments - Hainan Province has released a plan to enhance the quality of generic drugs, supporting the expedited registration and market entry of first generic products, particularly those that are urgently needed in clinics or have high prices or supply shortages [1] - The plan includes strengthening supervision of entrusted production and supporting consistency evaluations for the quality and efficacy of generic drugs, which will improve overall drug quality and ensure public safety [1] Drug and Device Approvals - Huasheng Technology's Sanqi Tongshu Capsules have been approved as the first secondary protected traditional Chinese medicine by the National Medical Products Administration, enhancing the company's core competitiveness in treating cardiovascular diseases [2] - United Imaging Healthcare's digital subtraction angiography system (DSA) uAngioAVIVA has received FDA approval, marking it as the first and only domestic DSA device allowed in the U.S. market [3] - Warner Pharmaceuticals has received a listing approval notice for potassium sulfate, which will enrich the company's product line and enhance its core competitiveness [4] - Xinhua Medical has obtained a Class II medical device registration certificate for its multi-chamber cleaning and disinfection device, which significantly reduces processing time compared to fully automatic devices [5] Financial Reports - Kelun Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.389 billion yuan, with a net profit decrease of 43.07% to 584 million yuan [6][7] - AstraZeneca's Q1 2025 revenue reached $13.588 billion, a 10% increase year-on-year, driven by double-digit growth in oncology and biopharmaceuticals [8] Capital Market Activities - Koser Medical Technology has completed nearly 100 million yuan in B+ round financing, which will be used for core product development and global market expansion [9] - Xellar Biosystems has secured several million yuan in strategic investment from XtalPi, aimed at accelerating the development of its organ-on-chip technology and expanding international collaborations [10] Industry Developments - Chen Yuqing has been appointed as the new chairman of Fosun Pharma, succeeding Wu Yifang, and will oversee the company's strategic development and organizational growth [11] - Merck has announced a $1 billion investment to build a production facility in Wilmington, Delaware, aimed at producing the next generation of biopharmaceuticals, including Keytruda [12] - Prilenia has entered a collaboration agreement with Ferrer for the oral sigma-1 receptor agonist Pridopidine, with a total deal value of up to €500 million [13] - Junshi Biosciences has signed a licensing agreement with Sandoz for its HLX13 monoclonal antibody, receiving an upfront payment of $31 million and potential milestone payments totaling $1.6 billion [14] Public Sentiment Alerts - Medici has announced that major shareholder Chen Jianhuang plans to reduce his stake by up to 2.23% between May 26 and August 25, 2025, due to personal funding needs [15]

华安证券股份有限公司 关于宁波长阳科技股份有限公司 2024年度持续督导工作现场检查报告 华安证券股份有限公司（以下简称"保荐机构"或"华安证券"）作为宁 波长阳科技股份有限公司（以下简称"长阳科技"或"公司"）2022年度向特 定对象发行股票并在科创板上市及持续督导的保荐机构，根据中国证监会《证 券发行上市保荐业务管理办法》以及《上海证券交易所上市公司自律监管指引 第11号——持续督导》等相关规定，对公司本持续督导期间的规范运作情况进 行了现场检查。现将本次现场检查情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 华安证券股份有限公司 （二）保荐代表人 何继兵、冯春杰 （三）现场检查时间 2025年4月21日至2025年4月22日 （四）现场检查人员 冯春杰、金宗辉 （五）现场检查内容 6、查阅公司定期报告、临时报告等信息披露文件； 7、核查本持续督导期间公司发生的关联交易、对外担保和对外投资情况； 8、检查公司、控股股东、实际控制人及董监高所做承诺及履行情况。 公司治理和内部控制情况、信息披露情况、公司的独立性以及与控股股东、 实际控制人及其他关联方资金往来情况、募集资金使用情况、关联交易、对外 ...

华安证券股份有限公司 关于宁波长阳科技股份有限公司 2024年度持续督导跟踪报告 华安证券股份有限公司（以下简称"保荐机构"、"保荐人"或"华安证券"） 作为宁波长阳科技股份有限公司（以下简称"长阳科技"或"公司"）2022年度 向特定对象发行股票并上市持续督导的保荐机构，根据《证券发行上市保荐业务 管理办法》、《上海证券交易所科创板股票上市规则》、《上海证券交易所上市 公司自律监管指引第11号——持续督导》等有关法律、法规的要求，负责长阳科 技本次股票发行上市后的持续督导工作，持续督导期间为2023年11月8日至2025 年12月31日。 2024年度，华安证券对长阳科技的持续督导工作情况总结如下： | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度， | 保荐机构已建立并有效执行了持续督导 | | 1 | 并针对具体的持续督导工作制定相应的 | | | | | 工作制度，并制定了相应的工作计划 | | | 工作计划 | | | | 根据中国证监会相关规定，在持续督导工 | 保荐机构已与长阳科技签订保荐协议， | | | 作开始前 ...

Revenue and Profit - Revenue for Q1 2025 was CNY 266,767,329.54, a decrease of 14.97% compared to the same period last year[4] - Net profit attributable to shareholders increased by 72.02% to CNY 14,162,433.12 from CNY 8,232,833.25 year-on-year[4] - Net profit after deducting non-recurring gains and losses rose by 95.43% to CNY 12,366,342.44[4] - The net profit for the first quarter of 2025 was CNY 14,162,433.12, an increase of 71.5% compared to CNY 8,232,833.25 in the same period of 2024[21] - The total comprehensive income for the first quarter of 2025 was CNY 14,146,285.09, compared to CNY 8,239,844.87 in the first quarter of 2024, representing an increase of 71.5%[21] Cash Flow and Investments - Operating cash flow for the period was CNY 23,510,284.85, a significant improvement from a negative cash flow of CNY -59,354,865.53 in the previous year[4] - The net cash flow from operating activities for the first quarter of 2025 was CNY 23,510,284.85, a significant improvement from a negative CNY 59,354,865.53 in the first quarter of 2024[23] - The net cash flow from investing activities for the first quarter of 2025 was CNY -43,716,439.81, an improvement from CNY -69,669,069.50 in the first quarter of 2024[24] - The company reported an investment loss of CNY -949,059.85 in the first quarter of 2025, compared to a gain of CNY 78,334.99 in the same period of 2024[20] Assets and Liabilities - Total assets at the end of the period were CNY 3,332,699,452.22, down 1.48% from the end of the previous year[5] - As of March 31, 2025, the company's total assets amounted to CNY 3,332,699,452.22, down from CNY 3,382,828,872.53 at the end of 2024[17] - The total liabilities decreased to CNY 1,231,084,280.15 from CNY 1,295,359,985.55, showing a reduction of approximately 5%[17] - Non-current assets totaled CNY 2,074,510,190.85, slightly down from CNY 2,079,264,944.54[16] - The company’s equity attributable to shareholders increased to CNY 2,101,615,172.07 from CNY 2,087,468,886.98, showing a modest increase[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,704[9] - The top shareholder, Jin Yadong, holds 15.70% of the shares, totaling 45,593,922 shares[10] Research and Development - R&D investment totaled CNY 13,451,230.91, a decrease of 17.31% year-on-year, with R&D expenses accounting for 5.04% of revenue[5] - Research and development expenses decreased to CNY 13,451,230.91 in the first quarter of 2025 from CNY 16,267,506.90 in the same period of 2024, reflecting a reduction of 17.3%[20] Inventory and Receivables - The company’s inventory decreased to CNY 250,060,300.67 from CNY 260,714,663.54, reflecting a decline of about 4%[15] - Accounts receivable increased to CNY 527,163,149.71 from CNY 516,752,803.29, indicating a rise of about 2.5%[15] Other Financial Metrics - The weighted average return on equity increased to 0.68%, up from 0.38% in the previous year[4] - The basic and diluted earnings per share for the first quarter of 2025 were both CNY 0.05, compared to CNY 0.03 in the first quarter of 2024, an increase of 66.7%[21] - Non-recurring gains and losses for the period amounted to CNY 1,796,090.68 after tax[7] - The company reported a significant decline in the price of lithium battery separators, which is expected to lead to substantial losses in 2024 due to increased competition and cost pressures[12] - The company has recognized credit impairment for specific accounts receivable, indicating potential risks of further impairment and customer claims if resolutions are not reached[12]